Treats acute, uncomplicated malaria infections due to Plasmodium falciparum (P.…. Sold as Coartem. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Artemether; Lumefantrine (sold as Coartem), first approved Apr 7, 2009, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Coartem | Part D | $54K | -35% | 119 |
| Ethiopian Antimalarial Therapeutic Efficacy Study 2026Plasmodium Vivax Malaria Without Complication, Plasmodium Falciparum Malaria (Uncomplicated) · Ethiopian Public Health Institute | — | Not yet recruiting | Sep 25, 2026 |
| Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)Uncomplicated Plasmodium Falciparum Malaria · Novartis Pharmaceuticals | Phase 2 | Recruiting | Sep 10, 2026 |
| Study to Assess Safety and Clinical Responses With Coartem® Baby Dispersible Tablets in Paediatric Patients Weighing 2 to <5 kg With Uncomplicated MalariaMalaria · Novartis Pharmaceuticals | Phase 4 | Not yet recruiting | Jul 20, 2026 |
| Safety and Efficacy of Imatinib in Combination With Artemether-Lumefantrine for Uncomplicated MalariaMalaria (Plasmodium Falciparum) · Victoria Biomedical Research Institute | Phase 2 | Recruiting | Apr 30, 2026 |
| Tafenoquine Combinations for Improved Radical Cure Efficacy of Plasmodium VivaxUncomplicated P. Vivax Mono-infection · Walter Reed Army Institute of Research (WRAIR) | Not applicable | Not yet recruiting | Apr 16, 2026 |
| Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated MalariaUncomplicated Malaria · Curtin University | Phase 4 | Not yet recruiting | Feb 11, 2026 |
| OPTImizing Malaria And HIV Treatment in a Shifting Landscape in AfricaMalaria, Hiv · Yale University | Phase 4 | Recruiting | May 13, 2025 |
| Safety of Antimalarials in the FIRst trimEsterMalaria, Pregnancy, Malaria, Antepartum · Liverpool School of Tropical Medicine | Phase 3 | Recruiting | May 8, 2025 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA